Abstract

Recent research has documented a wide range of health, economic, and social benefits conferred by vaccination, beyond the direct reductions in morbidity, mortality, and future healthcare costs traditionally captured in economic evaluations. In this paper, we describe the societal benefits that would likely stem from widespread administration of safe and effective vaccines against Streptococcus pyogenes (Strep A), which was estimated to be the fifth-leading cause of infectious disease deaths globally prior to the COVID-19 pandemic. We then estimate the global societal gains from prospective Strep A vaccination through a value-per-statistical-life approach. Estimated aggregate lifetime benefits for 30 global birth cohorts range from $1.7 to $5.1 trillion, depending on the age at which vaccination is administered and other factors. These results suggest that the benefits of Strep A vaccination would be large and justify substantial investment in the vaccines’ development, manufacture, and delivery.

Details

Title
The full health, economic, and social benefits of prospective Strep A vaccination
Author
Cadarette, Daniel 1   VIAFID ORCID Logo  ; Ferranna, Maddalena 2 ; Cannon, Jeffrey W. 3   VIAFID ORCID Logo  ; Abbas, Kaja 4   VIAFID ORCID Logo  ; Giannini, Fiona 3   VIAFID ORCID Logo  ; Zucker, Leo 5   VIAFID ORCID Logo  ; Bloom, David E. 5 

1  Harvard Kennedy School, Cambridge, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
2  University of Southern California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, Los Angeles, USA (GRID:grid.42505.36) (ISNI:0000 0001 2156 6853) 
3  University of Western Australia, Wesfarmers Centre for Vaccines and Infectious Diseases, Telethon Kids Institute, Perth, Australia (GRID:grid.1012.2) (ISNI:0000 0004 1936 7910) 
4  London School of Hygiene & Tropical Medicine, London, United Kingdom (GRID:grid.8991.9) (ISNI:0000 0004 0425 469X); Nagasaki University, School of Tropical Medicine and Global Health, Nagasaki, Japan (GRID:grid.174567.6) (ISNI:0000 0000 8902 2273) 
5  Harvard T.H. Chan School of Public Health, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
Pages
166
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20590105
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1038/s41541-023-00758-z
ProQuest document ID
2884013852
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.